Irreversible Inhibitor Dacomitinib CAS: 1110813-31-4 Polvo blanco

Superioridad

Zhongshan Latterson Biotechnology Co., Limitado., es una empresa farmacéutica integral, que se especializó en tecnología biofarmacéutica sobre 7 años. La empresa está ubicada en la ciudad de Zhongshan, Provincia de Guangdong , porcelana.
Nuestra fábrica cubre un área de 33500 metros cuadrados, con un ambiente limpio y un diseño agradable. Hay varios talleres grandes o medianos y un centro de investigación y control de calidad con equipos avanzados.. En el presente, Nuestros principales productos son la serie de esteroides anabólicos., Serie de péptidos, Serie de anestésicos locales. Nuestros productos alcanzan el estándar avanzado del mercado nacional., muchos de los cuales alcanzan el estándar internacional, los certificados contienen: COMESTIBLE SEGÚN LA LEY JUDÍA , YO ASI 9001:2008 , GMP , SGS.

Basic Information:

nombre del producto: Dacomitinib
Sinónimos: Dacomitinib;PF-00299804-03;PF-00299804;DacoMitinib (PF-00299804);DacoMitinib,PF299804;DacoMitinib (PF299804,PF-00299804);DacoMitinib (PF299804, PF299);(2mi)-NORTE-[4-[(3-Chloro-4-fluorophenyl)aminado]-7-methoxy-6-quinazolinyl]-4-(1-piperidinilo)-2-butenamide Dacomitinib (PF299804, PF299)
CASO: 1110813-31-4
MF: C24H25ClFN5O2
MW: 469.9390032
Solución antibacteriana necesaria en alcohol bencílico de aceite esteroide: 1.344

Descripción:

Dacomitinib is a selective and irreversible inhibitor of EGFR. It is a drug candidate for the treatment of non-small cell lung carcinoma. It is current under the Phase III clinical trials. It also shows potential for the treatment of HER-2 amplified breast cancer cells lines that are resistant to trastuzumab and lapatinib.

Biological activity:

Dacomitibib (Dacomitinib, PF299804) is an effective and irreversible pan-ErbB inhibitor that is most effective in EGFR, with an IC50 of 6 nM. It is also highly effective in NSCLCs that carries EGFR or ERBB2 mutants (against Gefitinib) and EGFR T790M mutant. Phase 2. Dacomitinib is taken orally once-daily. It is an irreversible inhibitor of HER-1 (EGFR), HER-2 and HER-4 tyrosine kinases. Dacomitinib targets multiple receptors of the HER pathway, whereas currently marketed HER-1 (EGFR) inhibitors for non-small cell lung cancer (NSCLC) target only one receptor in this pathway,developed by Pfizer.
Clinical Study Dacomitinib has advanced to several Phase III clinical trials. The results of the first trials were disappointing, with a failure to meet the study goals, Additional Phase III trials are ongoing. Clinical evaluation of dacomitinib is ongoing in a number of clinical trials in patients with advanced NSCLC across lines of therapies and a range of histologies and molecular subtypes, such as EGFR and KRAS status.
Además, there is an ongoing clinical trial evaluating dacomitinib in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).

Usos:

PF299804 is a potent, irreversible pan-ErbB inhibitor against ErbB1, ErbB2 and ErbB4 with IC50 of 6 nM, 45.7 nM and 73.7 nM, respectively.